Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial

What Was Tested

This clinical study looks at Somatostatin.

Desmoplastic small round cell tumor (DSRCT) and synovial sarcoma (SySa) are rare cancers primarily affecting adolescents and young adults.

Recently, overexpression of somatostatin receptors (SSTR) 2, 3, and 5 was described in high proportions of DSRCT and SySa.

Who Took Part

The abstract describes 5, participants taking part.

By PubMed's age tags, the people studied were teenagers, young adults and adults, both men and women.

Due to pasireotide's regulatory approval being limited to adults, enrollment follows a "3 + 3 staggered" approach for both adults and adolescents.

Treatment consists of pasireotide administered as intragluteal depot injection every 28±3 days.

How the Study Was Run

The researchers set it up as an open-label and multicenter study.

Everyone knew when Somatostatin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

Molecular eligibility is determined by SSTR2/3/5 expression via RNA analysis performed within the precision oncology programs MASTER and INFORM.

The primary endpoint is progression-free survival; secondary and exploratory analyses include overall survival, patient-reported outcomes, and disease monitoring via liquid biopsies.

Sensitivity analyses are planned for both age groups and disease types.

What Was Measured

PubMed files the paper under topics including Sarcoma, Synovial, Receptors, Somatostatin, Somatostatin, Desmoplastic Small Round Cell Tumor and Clinical Trials, Phase II as Topic.

The authors tagged it with the keywords 3 + 3 staggered approach, Maintenance treatment, Pasireotide, Precision oncology and Synovial sarcoma.

What This Means in Plain Language

The paper is an open-label and multicenter study of Somatostatin in 5, participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Cancer treatment and research communications), a journal based in England.

More context: the Somatostatin compound page, all human trials.